Novartis Disbands Cell Therapy Unit; What’s Ahead For Kite, Juno?

Things don't always work out. Just months before it is slated to seek regulatory approval for a new cancer therapy, Swiss drug giant Novartis ( NVS ) is disbanding its pioneering cell and gene therapy unit and folding it up into other parts of the company. The move now raises questions about the prospects for the widely-talked about field of CAR-T Therapies, as well as companies like Kite Pharmaceuticals ( KITE ) and Juno Therapeutics ( JUNO ).